Hugh Cole brings to Jounce more than 25 years of industry experience in pharmaceutical and biotech management. Before joining the team, Mr. Cole most recently served as chief business officer for ARIAD Pharmaceuticals, where in under three years, he led nine business development transactions for the company and helped develop and implement ARIAD’s new corporate strategy. In addition to his former role at ARIAD, Mr. Cole served as senior vice president, strategic planning and program management at Shire plc, where he oversaw the company’s portfolio management and rare disease strategic planning processes. At Shire, Mr. Cole was also globally responsible for the development strategy and commercialization of the rare disease drug Firazyr®, and led several important transactions for the company. Prior to joining Shire, Mr. Cole was vice president, corporate development for Oscient Pharmaceuticals and served as senior director, business development and strategy at Millennium Pharmaceuticals. Earlier in his career, Mr. Cole worked as a management consultant for The Wilkerson Group, a leading consultancy focused on life science companies and, prior to that, as an investment analyst for Fred Alger Management, where he covered the biotechnology and pharmaceutical industries.

Mr. Cole earned his MBA in health care management and finance at the Wharton School and his A.B. in chemistry from Harvard University.